ASCO 2026 - Complete program listing
June 2026
Daily recaps and interviews from the ASCO 2026
Dr. Kim Ma shares key ASCO 2026 updates in early breast cancer, including evidence supporting omission of axillary lymph node dissection in selected patients and promising neoadjuvant results from the Neo-Healer trial in HER2-positive disease.
Dr. Nathalie LeVasseur reviews key ASCO 2025 updates in early breast cancer, highlighting emerging evidence supporting treatment optimization, opportunities for de-escalation in biologically low-risk disease, and the growing role of metabolic and lifestyle interventions in improving patient outcomes.
Dr. Mita Manna reviews ASCO 2026 data on GLP-1 receptor agonists, breast cancer outcomes, and emerging links between social determinants and tumor biology.
Dr. Katarzyna Jerzak reviews ASCO 2026 updates from HER2CLIMB-05, highlighting tucatinib maintenance in HER2-positive metastatic breast cancer and its implications for upcoming REAL Alliance Canadian consensus recommendations.
Dr. Jamil Asselah reviews the most impactful breast cancer updates from ASCO 2026, including OPTIMA, ctDNA-guided treatment strategies, DESTINY-Breast09, and emerging applications of AI in precision oncology.
Dr. Christine Brezden-Masley reviews the ASCO 2026 OPTIMA trial, highlighting how Prosigna-guided treatment identified many high-risk ER-positive, HER2-negative patients who may safely avoid chemotherapy while achieving excellent outcomes.
Dr. Zahi Mitri highlights the ASCO 2026 studies most likely to shape breast cancer care, from ADCs and HER2-targeted therapies to oral SERDs, ctDNA-guided treatment, and genomic testing.
Comments (0)